FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia
Dateline City:
WHITEHOUSE STATION, N.J.
BELSOMRA expected to be available in late 2014 or early 2015
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
approved BELSOMRA® (suvorexant) for adults with insomnia who
have difficulty falling asleep and/or staying asleep. BELSOMRA
(pronounced bell-SOM-rah) is a highly selective antagonist for orexin
receptors. Orexin is a neurotransmitter found in a specific part of the
brain that can help keep a person awake.
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 267-305-3558Megan Wilkinson, 267-305-6463orInvestor Contacts:Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Brain | Drugs & Pharmacology | Food and Drug Administration (FDA) | Insomnia | Merck | Neurology